Logo

Hologic Acquires Focal Therapeutics for $125M to Strengthen its Breast Surgery Platform

Share this

M&A

Hologic Acquires Focal Therapeutics for $125M to Strengthen its Breast Surgery Platform

Shots:
  • Hologic to acquire Focal for its BioZorb marker- an implantable 3D marker helping surgeons to overcome challenges in breast conserving surgery- or lumpectomy used to mark tumor excision site
  • The acquisition on focus on treating breast cancer patients by improving Qol with 3D indicator at surgical site
  • The US FDA has already granted 510(k) clearance to BioZorb- available in a range of sizes. The transaction is expected to close in Oct 2018
/ article | Ref: Hologic | Image: Ofordglobal

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions